Thu.Dec 14, 2023

article thumbnail

Mediterranean Diet Could Help Reduce Adverse Pregnancy Outcomes

Drug Topics

The mediterranean diet targets inflammation, oxidative stress, and hormonal balance mechanisms, which are also associated with female reproductive outcomes.

187
187
article thumbnail

From Fear to Passion: Embracing the Unexpected Journey into Pediatric Pharmacy with Dr. Stephen Small!

Pharmacy Is Right For Me

An Unexpected Path Deciding exactly what you want to do or where you want to go in life is difficult. What if you don’t like where you end up? What if you change your mind? Dr. Stephen Small is a prime example of what it looks like to not only change your mind but to embrace the unexpected. Dr. Small is a pediatric clinical pharmacist specialist but if you had asked him years earlier, he would not have thought that he would end up working with children, “Pediatrics was actually the only specialt

Hospitals 162
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Combined Influenza, COVID-19 Vaccines Offer Strongest Protection for Children

Drug Topics

While either vaccine offers some protection, having both vaccines offers the strongest level of protection against hospitalization and severe complications like MIS-C, and death.

Vaccines 181
article thumbnail

Pharmacy Automation Can Be a Means to Drug Safety

Pharmacy Times

In the pharmacy, time is the ultimate value-add.

158
158
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Done deal: Pfizer completes $43B acquisition of Seagen, doubling its oncology pipeline

Fierce Pharma

Pfizer’s $43 billion acquisition of Seagen is in the books, the company said on Thursda | It’s a done deal. Pfizer’s $43 billion acquisition of Seagen is in the books, as it becomes the largest M&A transaction in the biopharma industry since AbbVie snatched up Allergan for $63 billion in 2019. The buyout of the antibody-drug conjugate specialist has doubled Pfizer’s pipeline to 60 programs.

145
145
article thumbnail

Litfulo From Pfizer Inc

Pharmacy Times

The approval carries the limitation that ritlecitinib should not be used in combination with biologic immunomodulators, cyclosporine, other Janus kinase inhibitors, or other potent immunosuppressants.

149
149

More Trending

article thumbnail

Alternative Funding Programs Affect Our Most Vulnerable Patient Populations

Pharmacy Times

AFPs limit access to provider-prescribed specialty medications.

146
146
article thumbnail

STAT+: Sanders blames food companies for diabetes epidemic

STAT

WASHINGTON — Sen. Bernie Sanders (I-Vt.) has a new corporate target: the food industry. Sanders held a hearing today on diabetes that implicated both the food and drug industries in what the American Diabetes Association estimates is a $413 billion annual cost to the health care system. That’s up 27% over the past six years, he said, and he warned that new weight loss drugs could send health care spending to the stratosphere.

138
138
article thumbnail

Researchers Design Flu Vaccine With Improved Protection From Influenza A Strains

Pharmacy Times

The results found that the M2e nanoparticle injection could efficiently protect individuals from influenza A viruses.

Vaccines 139
article thumbnail

STAT+: In response to criticism, FDA publishes new database of wayward clinical trial sponsors

STAT

In a bid toward greater transparency, the U.S. Food and Drug Administration earlier this month launched a dashboard containing preliminary notices sent to companies, universities, and researchers that failed to register clinical trials or report study results. The agency has so far sent about 120 so-called pre-notices indicating a clinical trial sponsor or investigator failed to comply with a federal law that requires such steps.

FDA 136
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

FDA Approves Elfornithine for the Treatment of High-Risk Neuroblastoma in Adult, Pediatric Patients

Pharmacy Times

This is the first FDA approval for a therapy intended to reduce the risk of relapse in patients with high-risk neuroblastoma.

FDA 139
article thumbnail

North Carolina attorney general sues HCA for lapses at Mission Health

STAT

North Carolina’s attorney general alleges in a new lawsuit that HCA Healthcare is violating the terms of the agreement that allowed it to buy Mission Health, a formerly nonprofit health system. In the complaint filed Thursday , attorney general Josh Stein said HCA, the country’s largest for-profit hospital chain, is not providing the quality, consistent emergency and cancer care that it committed to delivering across Mission’s six western North Carolina hospitals.

Hospitals 134
article thumbnail

Generic Product News: December 2023

Pharmacy Times

The products include Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution, Icatibant Injection, Esomeprazole Magnesium Capsules, and Apremilast Tablets.

139
139
article thumbnail

STAT+: Jay Bradner, former Novartis research leader, to head up Amgen’s scientific efforts

STAT

Jay Bradner, a former top research leader at Novartis, is joining Amgen as its new chief scientific officer, the California company announced Thursday.   Bradner is taking over for Amgen veteran David Reese in the role. Reese is becoming the company’s chief technology officer. “For more than 40 years, Amgen’s focus on innovation has enabled us to deliver life-changing medicines to patients suffering from serious diseases around the world,” Robert Bradway, Am

128
128
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

FDA Approves Updated Label for Bempedoic Acid, Ezetimibe Tablets

Pharmacy Times

The update also removed the maximally tolerated qualifier for statin use and the statement that said morbidity and mortality was not yet determined.

Labelling 139
article thumbnail

Bluebird signs major coverage deal for sickle cell gene therapy Lyfgenia, easing some price concerns

Fierce Pharma

Despite the high list price of Lyfgenia, bluebird has signed a large reimbursement deal for the sickle cell disease (SCD) gene therapy less than a week after its

127
127
article thumbnail

Navigating C. Diff During the COVID-19 Pandemic, The Impact of Antibiotic Usage and Surgeries

Pharmacy Times

Feldman details her experience with C. diff, how the COVID-19 pandemic slowed the timeline of care, and how her surgical history and the use of antibiotics played into the disease’s onset.

139
139
article thumbnail

Oracle's Q2 revenue comes up short dragged by Cerner business, slower cloud growth

Fierce Healthcare

Oracle's second-quarter revenue fell short of analysts' expectations, dragged down by its Cerner business and slowing cloud growth. | Oracle is using its tech muscle to add new capabilities to the Millennium EHR, chairman Larry Ellison said. "We are going after a much larger market than Cerner was. We expect Cerner to be a growth story," he told investors during Oracle's Q2 earnings call.

Cerner 127
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Health records don’t always show when patients are dead. One researcher is trying to change that

STAT

Health professor Neil Wenger was deep into a years-long study on seriously ill primary care patients when he uncovered a different but persistent issue: Many patients who were targeted for follow-up interventions had actually died, and their hospitals did not know about it. It wasn’t what Wenger had set out to research. But it was unacceptable, he said, for health systems to lose track of seriously ill primary care patients who’d been treated on-site for years.

Hospitals 122
article thumbnail

Biden administration flags dozens of pharma companies to pay Medicare rebates for 'outrageous' price hikes

Fierce Healthcare

The Biden administration is cracking down on pharmaceutical companies as part of its price-fighting measures under the Inflation Reduction Act. | The Biden Administration announced Thursday a list of 48 Part B drugs with prices that rose faster than the rate of inflation in the final quarter of 2023. Here's what they plan to do now.

article thumbnail

Reinventing drug invention

pharmaphorum

Reinventing drug invention Mike.

122
122
article thumbnail

Healthcare industry celebrates, honors NACDS’ 90th anniversary, retail pharmacies

Drug Store News

The healthcare industry joined together Wednesday night in New York City to honor and celebrate NACDS’ 90th anniversary, while also paying tribute to pharmacy retailers.

118
118
article thumbnail

AI drug discovery: Where we are and where we’re going

pharmaphorum

AI drug discovery: Where we are and where we’re going Mike.

119
119
article thumbnail

STAT+: Amputees have better balance, less pain after electrical stimulation, study finds

STAT

For years, Lauren Gavron relied on oxycodone to quiet the pain in her missing lower left limb. But she hated the fog that came with it, preventing her from feeling comfortable enough to drive. When researchers at the University of Pittsburgh delivered electric jolts to her spine in 2021, the Duquesne, Pennsylvania resident was shocked to feel that pain temporarily melt away — and to feel sensation in her prosthetic foot, improving her walk and balance.

118
118
article thumbnail

Speakers at DSN's Industry Issues Summit discuss big trends, such as AI, health equity, the future of pharmacy

Drug Store News

Drug Store News held its 25th annual Industry Issues Summit in New York City on Dec. 13, where industry leaders weighed in on a myriad of challenges and opportunities.

116
116
article thumbnail

Opinion: Europe’s lessons for the U.S. on how to cover weight loss drugs

STAT

It’s no secret that the obesity epidemic in the United States has reached alarming levels, with rates surpassing 40% of the population. Despite a robust focus on wellness and exercise in the media, post-pandemic America continues to rank among the global leaders in obesity rates. Estimates indicate that treating obesity will be expensive, but those sums pale in comparison to the estimated direct and indirect costs of $1.7 trillion that obesity places on the U.S. health care system today.

Insurance 116
article thumbnail

Understanding the evidence used in drug product withdrawals

European Pharmaceutical Review

In the ever-evolving landscape of regulatory decisions, the quest for safeguarding public health remains paramount. Decisions to remove medicines from market are not taken lightly and are often based upon all evidence available to inform a benefit/risk balance. This evidence can come from a range of sources, such as randomised controlled trials (RCTs), observational studies, and spontaneous reporting.

article thumbnail

Evaluating Multiple Myeloma Survival Rates by Race, Ethnicity, and Rural-Urban Location

Drug Topics

Data from the Surveillance, Epidemiology, and End Results (SEER) database were reviewed.

112
112
article thumbnail

Photo Gallery: NACDS’ 90th Anniversary

Drug Store News

Check out photos from the celebration of the National Association of Chain Drug Stores’ 90th anniversary.

112
112
article thumbnail

Slideshow: Examining the Treatment Landscape for Chronic Lymphocytic Leukemia

Drug Topics

Six posters presented at the 65th American Society of Hematology Annual Meeting and Exposition looked at how treatments are impacting care for this patient population.

112
112
article thumbnail

STAT+: Why FDA product recalls have spiked in recent years

STAT

Either American products are getting worse, or scrutiny over their safety is getting tougher. Whichever the case, product recalls by the Food and Drug Administration and the Consumer Product Safety Commission (CPSC) more than doubled between 2018 and 2022, according to new research published on Wednesday by life sciences software company MasterControl.

FDA 111
article thumbnail

White House says 48 drugs are heading for Medicare rebates

pharmaphorum

White House says 48 drugs are heading for Medicare rebates Phil.

111
111
article thumbnail

US WorldMeds' Iwilfin bags FDA nod as 1st oral maintenance treatment for high-risk neuroblastoma

Fierce Pharma

While existing neuroblastoma treatments can help patients achieve remission, sustaining that remission has proven tricky. But now, patients and doctors have a new oral option. | The U.S. FDA has approved US WorldMeds’ Iwilfin—also known as eflornithine—as a new oral maintenance therapy for high-risk neuroblastoma. The drug, cleared in 192 mg tablets, is indicated to cut the risk of relapse in kids and adults with high-risk neuroblastoma who’ve had at least a partial response to prior treatment.

FDA 111